IDXX insider Hunt exercises 1,226 options, reports sale of 1,200 shares
Rhea-AI Filing Summary
Nimrata Hunt, Executive Vice President of IDEXX Laboratories, reported transactions in the issuer's common stock (ticker IDXX). The filing shows a sale and subsequent option exercises that largely offset each other. On 08/11/2025 she sold 1,200 shares at $656.5335, leaving 16,806.9435 shares held directly. On 08/12/2025 she acquired shares through the exercise of previously granted options: 560 at $178.26, 483 at $206.94, and 183 at $544.08, bringing direct beneficial ownership to 18,032.9435 shares. The filing also notes 160 shares held indirectly, jointly with a spouse. The exercised options correspond to grants that became exercisable in one installment on Feb 14, 2023, Feb 14, 2024, and Feb 14, 2025.
Positive
- Exercises of long-standing option grants (became exercisable in 2023, 2024 and 2025) indicate alignment with equity compensation schedules
- Net direct holdings increased to 18,032.9435 shares after reported transactions
Negative
- Sale of 1,200 shares on 08/11/2025 by an executive could be viewed by some investors as a liquidity event
- 160 shares held indirectly jointly with spouse adds a layer of indirect ownership that investors may note for governance context
Insights
TL;DR: Routine option exercises and a small sale by an executive; net share holdings increased modestly.
The filing documents a sale of 1,200 shares followed by the exercise of 1,226 option-based rights, resulting in a net increase of 26 shares in direct beneficial ownership to 18,032.9435 shares. The exercises were of incentive stock options with stated exercise prices of $178.26, $206.94 and $544.08. These appear to be exercises of previously granted awards that became exercisable in annual installments, which is common compensation behavior and not, on its face, a material change to ownership for a large-cap issuer.
TL;DR: Transactions align with equity-based compensation schedules; sale likely routine rather than signaling governance concerns.
The report shows exercises tied to option grants that became exercisable in specified prior years and a contemporaneous sale of 1,200 shares. The filing notes 160 shares held indirectly with a spouse. From a governance perspective, these disclosures illustrate standard executive participation in equity programs and transparent reporting under Section 16. There is no explicit indication of unusual timing or related-party transaction beyond the spouse-held shares disclosed as indirect ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (right-to-buy) | 560 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 483 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 183 | $0.00 | -- |
| Exercise | Common Stock | 560 | $178.26 | $100K |
| Exercise | Common Stock | 483 | $206.94 | $100K |
| Exercise | Common Stock | 183 | $544.08 | $100K |
| Sale | Common Stock | 1,200 | $656.5335 | $788K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2023. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2024. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.
